Evercore ISI analyst Vijay Kumar raised the firm’s price target on Boston Scientific to $78 from $72 and keeps an Outperform rating on the shares as the firm said the company reported “solid results and there wasn’t much to pick on.” While EP franchise acceleration driven by Farapulse PFA launch “is generally well known” by the Street, the firm says it doesn’t think “anyone expected ~86% US growth and ~72% International growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific sees FY24 adjusted EPS $2.29-$2.34, consensus $2.25
- Boston Scientific sees Q2 adjusted EPS 57c-59c, consensus 56c
- Boston Scientific reports Q1 adjusted EPS 56c, consensus 51c
- Boston Scientific Announces Results for First Quarter 2024
- Notable companies reporting before tomorrow’s open